A Single-Arm, Multicenter, Open-Label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of VG161 in the Treatment of Advanced Intrahepatic Cholangiocarcinoma
Latest Information Update: 30 Dec 2024
Price :
$35 *
At a glance
- Drugs VG 161 (Primary)
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
- Sponsors Virogin Biotech
- 30 Dec 2024 New trial record